VACCINE EFFICACY TRIALS PIPELINE

- **RV144**
  - 31% efficacy
  - 2003-2009
  - ALVAC/AIDSVAX Clade B, A/E Thailand

- **Ad26**
  - Janssen
  - Phase I MVA mosaic boost USA
  - Phase I gp140 + adjuvant USA
  - Phase I/II Ad26.Mos HIV + Ad26, MVA or gp140 boost: Rwanda, South Africa, Thailand, Uganda, USA

- **Pox-Protein**
  - PS, GSK, Sanofi Pasteur

- **PrEPVacc**
  - Imperial College, MRC/UVRI & LSHTM, EDCTP, UCL, IAVI, CHUV/EF
  - PRPVacc Registration Cohort

**Development Track**
- South Africa
- Designed to lead to a product submitted for regulatory approval and eventual public health introduction.
- Phase Iib/III ALVAC/gp120 Clade C
- Estimated completion: July 2021

**Research Track**
- Southern Africa and US
- Designed to identify components of an effective vaccine strategy.
- Phase I and I/IIa prime-boost candidates with varying vectors, primes, boosts and adjuvants: Clade C

**PrEPVacc**
- EST. 2020-2023
- Phase Iib DNA+/AIDSVAX Clade B/E or DNA+/gp140 Clade C/MVA+gp140 Clade C with TAF/FTC or TDF/FTC: Mozambique, South Africa, Tanzania, Uganda

**KEY:**
- Completed
- Ongoing
- Planned